MD, at UZ Gent, Belgium.
Jeroen Geldof, MD is a Gastroenterology consultant currently serving as adjunct kliniekhoofd at University Hospital UZ Ghent, Belgium. He has extensive expertise in gastroenterology, particularly in inflammatory bowel disease (IBD) and proctology, with numerous international collaborations and research contributions in these fields. Dr. Geldof has held fellowships in prestigious institutions such as St. Mark’s Hospital in London and CHU Rennes in France. His work bridges clinical practice and research, with a strong focus on improving patient outcomes through multidisciplinary approaches.
Profile
ORCID
Education
Dr. Geldof holds multiple advanced degrees, starting with a Master of Medicine (great distinction) from Ghent University in 2013, followed by a Master of Specialist Medicine in Gastroenterology from the same institution in 2019. He also completed a Bachelorclass Course in Abdominal Ultrasound at the Medical University of Vienna, Austria in 2017. Additionally, he achieved certifications in proctology from Université Paris Cité and management from UZ Gent.
Experience
Dr. Geldof’s professional journey includes residencies and fellowships across several notable medical centers in Belgium and the UK, including St. Mark’s Hospital and CHU Rennes. He has specialized in gastroenterology with a focus on IBD and proctology, working closely with international experts like Prof. Dr. Ailsa Hart and Prof. Dr. Laurent Siproudhis. Since 2019, he has been practicing as a Gastroenterology consultant at University Hospital UZ Ghent, where he continues to expand his expertise in gastrointestinal diseases.
Research Interests
Dr. Geldof’s research interests are centered on inflammatory bowel diseases (IBD), perianal fistulas, and the multidisciplinary treatment of complex gastrointestinal conditions. He also has a keen interest in colorectal cancer prevention, evidenced by his publications and ongoing collaborations. His research has contributed to clinical advancements in both medical and surgical treatments for patients with complex gastrointestinal diseases.
Awards & Certifications
Dr. Geldof has earned several prestigious certifications, including the European Specialty Examination in Gastroenterology and Hepatology (ESEGH) in 2019 and the GCP Certificate of Good Clinical Practices. He continues to be recognized for his contributions to gastroenterology through various certifications, such as the Diplôme interuniversitaire de Proctologie from Université Paris Cité in 2023.
Publications
Dr. Geldof has published extensively in peer-reviewed journals. Here are some selected publications:
- Geldof J, et al. (2023).
- Title: SARS-CoV-2 infection and COVID-19 vaccination across eight immune-mediated inflammatory disorders: A prospective, real-life Belgian cohort study – the BELCOMID study.
- Published in: Frontiers in Immunology
- Cited by: 15 articles
- Summary: This study investigates the effects of SARS-CoV-2 infection and COVID-19 vaccination across a cohort of patients with eight different immune-mediated inflammatory disorders (IMIDs). The study provides real-life data on the safety and efficacy of vaccination in these patient populations.
- Holvoet T, Truyens M, Geldof J, et al. (2024).
- Title: Safety and Effectiveness of Vedolizumab and Ustekinumab in Elderly Patients with Inflammatory Bowel Disease: A Real-Life Multicentric Cohort Study.
- Published in: Journal of Clinical Medicine
- Cited by: 5 articles
- Summary: This study examines the safety and effectiveness of Vedolizumab and Ustekinumab in elderly patients with inflammatory bowel disease (IBD). It is a multicentric cohort study, providing real-life evidence on the treatment of IBD in older populations.
- Geldof J, et al. (2022).
- Title: Classifying perianal fistulising Crohn’s disease: An expert consensus to guide decision-making in daily practice and clinical trials.
- Published in: The Lancet Gastroenterology & Hepatology
- Cited by: 45 articles
- Summary: This paper presents expert consensus on the classification of perianal fistulising Crohn’s disease, aiming to improve decision-making in both clinical practice and clinical trials. The classification system developed is intended to standardize how this challenging aspect of Crohn’s disease is managed and studied.
Conclusion
Jeroen Geldof’s combination of clinical expertise, research contributions, and active participation in international collaborations make him a highly suitable candidate for the Best Researcher Award. His work in gastroenterology, especially in IBD, highlights his commitment to advancing medical knowledge and improving patient outcomes. Addressing areas for further research expansion and public engagement will continue to elevate his profile in the field.